Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy – Genetic Engineering & Biotechnology News (press release)
|
Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy
Genetic Engineering & Biotechnology News (press release) Kite Pharma said today it has submitted to the FDA an Investigational New Drug (IND) application to launch a Phase I, first-in-human trial of a chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) in patients … |
